Account
News

PMA Insights: Week 7

17/02/2023
  • CEPs Annual Report indicates reduced time to market access
  • The FDA’s Biosimilar User Fee Amendments III (BsUFA III)
15022023-News-Digest-Wk-7Download

Author:

Amy Rudd, ACIM
About the Author

Article Tags

Biosimilars Funding Gene Therapy & ATMPs HTA PMA Trends Pricing

Share this article

Related articles

Articles
19.05.2025
Avoiding Common Pitfalls in HTA Scientific Advice:...

With the implementation of the EU HTA (Regulation (EU) 2025/117) and ongoing adaptation of methods u...

Read more
Articles
12.05.2025
Driving Internal Alignment: How Early HTA Advice U...

As the regulatory and market access landscape continues to evolve across Europe, timely and strategi...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch